Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
暂无分享，去创建一个
[1] J. Xu,et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.
[2] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[3] A. Jørgensen. Weill Cornell Medical College/New York Presbyterian Hospital , 2011 .
[4] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[5] J. Stockman. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2009 .
[6] R. Kozarek,et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab , 2007, Inflammatory bowel diseases.
[7] I. Urosevic,et al. Autoantibodies to Mitotic Apparatus: Association with Other Autoantibodies and Their Clinical Significance , 2006, Journal of Clinical Immunology.
[8] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .